Medical Radiology and Radiation Safety. 2024. Vol. 69. № 6
DOI:10.33266/1024-6177-2024-69-6-82-86
M.A. Iliin1, M.V. Podolskaya2
Rotational Volume-Modulated Radiation Therapy of Unresectable
Localised Form of Castleman’s Disease
¹ FSBI Russian Scientific Center for Roentgenoradiology, Moscow, Russia
2 RUDN University, Moscow, Russia
Contact person: Mariya V. Podolskaya, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Rеlevance: Castleman’s disease is a relatively rare heterogeneous group of lymphoproliferative diseases, the incidence of the localized form is 15, and the multicentric form is about 5 people per 1 million population. Currently, surgical treatment is the most radical in the treatment of localized forms of Castleman’s disease, and in cases where the clinical situation is considered unresectable, the treatment strategy is not strictly defined. Studies of the effect of radiation therapy on the survival rates of patients with Castleman’s disease remain isolated to this day, up to the description of individual clinical cases. This is due to the low incidence of this pathology, which does not allow for high-power randomized clinical trials. However, empirical accumulation of experience suggests that conducting remote radiation therapy in total doses of 40 Gy helps to achieve long-term local control. The use of modern methods of radiation therapy in the form of volume-modulated radiation therapy makes it possible to avoid serious post-radiation damage to healthy organs and tissues adjacent to the tumor, and can help in achieving stable local control in the treatment of unrecoverable forms. It is possible to use DLT protocols used in the treatment of lymphomas, which may be comparable in their effectiveness for Castleman’s disease, which requires subsequent research.
Purpose: Аn analysis of a rare clinical observation of the successful use of rotational volume-modulated radiation therapy in the treatment of an unresectable localized form of Castleman’s disease.
Material and methods: The search and analysis of literature data in Russian and English for the period from 2000 to 2023 in the databases Medline/PubMed, RSCI/Elibrary, CyberLeninka, Google Scholar, devoted to the diagnosis and treatment of Castleman’s disease. Clinical observation of the use of rotational volume-modulated radiation therapy in the treatment of an unresectable localized form of Castleman’s disease with lesions of the supraclavicular lymph nodes (hyaline-vascular type, unicentric variant).
Results: Rotational volume-modulated radiation therapy of an unresectable localized form of Castleman’s disease can have a stable and safe consolidating effect in the form of long-term local control.
Keywords: Castleman’s disease, radiation therapy, clinical case
For citation: Iliin MA, Podolskaya MV. Rotational Volume-Modulated Radiation Therapy of Unresectable Localised Form of Castleman’s Disease. Medical Radiology and Radiation Safety. 2024;69(6):82–86. (In Russian). DOI:10.33266/1024-6177-2024-69-6-82-86
References
1. Dispenzieri A., Armitage J.O, Loe M.J, et al. The Clinical Spectrum of Castleman’s Disease. Am. J. Hematol. 2012; Nov;87;11:997–1002. DOI: 10.1002/ajh.23291.
2. Simpson D. Epidemiology of Castleman Disease. Hematol. Oncol. Clin. N. Am. 2018;32:1–10. DOI: 10.1016/j.hoc.2017.09.001.
3. Talat N., Schulte K.M. Castleman’s Disease: Systematic Analysis of 416 Patients from the Literature. Oncologist. 2011;16:1316-1324. DOI: 10.1634/theoncologist.2011-0075.
4. Iwaki N., Fajgenbaum D.C., Nabel C.S, et al. Clinicopathologic Analysis of TAFRO Syndrome Demonstrates a Distinct Subtype of HHV-8-Negative Multicentric Castleman Disease. Am. J. Hematol. 2016;91:220-226. DOI: 10.1002/ajh.24242.
5. Nishimura Y., Hanayama Y., Fujii N., et al. Comparison of the Clinical Characteristics of TAFRO Syndrome and Idiopathic Multicentric Castleman Disease in General Internal Medicine: a 6-year Retrospective Study. Intern. Med. J. 2020;50:184-191. DOI:10.1111/imj.14404.
6. Talat N., Belgaumkar A.P., Schulte K.M. Surgery in Castleman’s Disease: a Systematic Review of 404 Published Cases. Ann. Surg. 2012;255:677-684. DOI: 10.1097/SLA.0b013e318249dcdc.
7. Wu D., Lim M.S., Jaffe E.S. Pathology of Castleman Disease. Hematol. Oncol. Clin. North. Am. 2018;32:37-52. DOI: 10.1016/j.hoc.2017.09.004.
8. Fajgenbaum D.C., Uldrick T.S., Bagg A., et al. International, Evidence-Based Consensus Diagnostic Criteria for HHV-8-Negative/Idiopathic Multicentric Castleman Disease. Blood. 2017;129:1646-1657. DOI: 10.1016/j.hoc.2017.09.004.
9. Van Rhee F., Oksenhendler E., Srkalovic G., et al. International Evidence-Based Consensus Diagnostic and Treatment Guidelines for Unicentric Castleman Disease. Blood. Adv. 2020;4:6039-6050. DOI: 10.1182/bloodadvances.2020003334.
10. Van Rhee F., Voorhees P., Dispenzieri A., et al. International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease. Blood. 2018;132:2115-2124. doi:10.1182/blood-2018-07-862334.
11. Van Rhee F., Casper C., Voorhees P.M., et al. Long-Term Safety of Siltuximab in Patients with Idiopathic Multicentric Castleman Disease: a Prespecified, Open-Label, Extension Analysis of Two Trials. Lancet. Haematol. 2020;7:e209-e217. DOI:10.1016/s2352-3026(19)30257-1.
12. Van Rhee F., Rosenthal A., Kanhai K., et al. Siltuximab is Associated with Improved Progression-Free Survival in Idiopathic Multicentric Castleman Disease. Blood. Adv. 2022;6:4773-4781. DOI: 10.1182/bloodadvances.2022007112.
13. Chronowski G.M., Ha C.S., Wilder R.B., et al. Treatment of Unicentric and Multicentric Castleman Disease and the Role of Radiotherapy. Cancer. 2001;92:670-676. DOI:10.1002/1097-0142(20010801)92:3<670:aid-cncr1369>3.0.co;2-q
14. Matthiesen C., Ramgopol R., Seavey J., Ahmad S., Herman T. Intensity Modulated Radiation Therapy (IMRT) for the Treatment of Unicentric Castlemans Disease: a Case Report and Review of the Use of Radiotherapy in the Literature. Radiology and Oncology. 2012;46;3:265-70. DOI:10.2478/v10019-012-0008-0
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.07.2024. Accepted for publication: 25.09.2024.